In an adult with isolated nausea and vomiting without abdominal pain, heartburn, or diarrhea, should ondansetron, domperidone, or omeprazole be used as first‑line therapy?

Ondansetron is the preferred first-line agent for isolated nausea and vomiting in adults without gastroparesis

For an adult presenting with isolated nausea and vomiting without abdominal pain, heartburn, or diarrhea, ondansetron should be used as first-line therapy. Omeprazole has no role in treating nausea/vomiting (it treats acid-related symptoms like heartburn), and domperidone is not FDA-approved in the United States and requires special investigational access 1.

Clinical Reasoning

Why Ondansetron Wins

Ondansetron is a 5-HT3 receptor antagonist that blocks serotonin receptors in both the chemoreceptor trigger zone and vagal afferents, providing direct antiemetic effects 2. In the emergency department setting—which mirrors your clinical scenario of acute isolated nausea/vomiting—ondansetron demonstrates equivalent efficacy to other antiemetics while offering superior safety 3, 4.

• Efficacy: A 2025 Bayesian network meta-analysis found intravenous ondansetron ranked highest (SUCRA=78.6%) for not causing significant adverse reactions among ED patients 4. Multiple trials show ondansetron reduces nausea scores comparably to dopamine antagonists 5, 6.

• Safety profile: Ondansetron is not associated with sedation or extrapyramidal symptoms (akathisia, dystonia) that plague metoclopramide and prochlorperazine 3, 6. The FDA label notes QT prolongation risk, but this is manageable with ECG monitoring in high-risk patients 7.

• Dosing: 4-8 mg orally or IV every 8 hours 2, 7.

Why NOT Omeprazole

Omeprazole is a proton pump inhibitor that reduces gastric acid secretion. It has zero antiemetic properties and does not treat nausea or vomiting 8. It only addresses acid-related symptoms like heartburn or gastritis. Your patient has no heartburn, making omeprazole completely inappropriate.

Why NOT Domperidone (in the US)

While domperidone is a dopamine D2 antagonist with prokinetic and antiemetic effects, it is not FDA-approved in the United States 1. The 2025 AGA gastroparesis guidelines explicitly recommend against domperidone as first-line treatment even for gastroparesis patients 1.

Critical barriers to domperidone use:

• Requires FDA investigational new drug (IND) application for expanded access 1
• Current US supplier is exiting the market 1
• Requires baseline ECG, potassium, and magnesium monitoring due to QT prolongation risk 1
• Reserved for patients who failed metoclopramide or have contraindications to it 1, 2

Even in countries where domperidone is available, a 2026 long-term study showed only 36% of patients continued treatment, with discontinuation due to lack of efficacy (114 patients) or side effects including palpitations, QTc prolongation, and chest pain 9.

Important Context: Is This Gastroparesis?

Your patient has isolated nausea/vomiting without abdominal pain, heartburn, or diarrhea. This presentation could represent:

1. Acute gastroenteritis/viral illness (most common in ED) 6
2. Functional nausea/vomiting
3. Early gastroparesis (requires 4-hour gastric emptying study for diagnosis) 1

The 2025 AGA gastroparesis guidelines are NOT applicable here because:

• Gastroparesis diagnosis requires documented delayed gastric emptying on 4-hour testing 1
• Even for confirmed gastroparesis, the guidelines suggest metoclopramide or erythromycin as first-line, NOT domperidone 1
• Ondansetron is explicitly mentioned as appropriate for symptomatic nausea/vomiting management in gastroparesis patients as an "as-needed" antiemetic 1

Practical Algorithm

Step 1: Rule out red flags requiring different management:

• Bowel obstruction (absent bowel sounds, distension)
• Acute abdomen (peritoneal signs)
• Medication-induced (opioids, GLP-1 agonists)
• Metabolic causes (hypercalcemia, uremia)

Step 2: For isolated nausea/vomiting:

• First-line: Ondansetron 4-8 mg PO/IV every 8 hours 2, 7
• Add IV fluids for dehydration 5, 10

Step 3: If ondansetron fails after 24-48 hours:

• Consider metoclopramide 10 mg PO/IV three times daily (watch for akathisia) 2
• Or prochlorperazine 5-10 mg PO/IV four times daily 2

Step 4: If symptoms persist beyond 1 week:

• Order 4-hour gastric emptying study to evaluate for gastroparesis 1
• Consider upper endoscopy to rule out mechanical obstruction

Common Pitfalls

1. Using omeprazole for nausea: This is a fundamental error. PPIs treat acid, not nausea. Only use if heartburn/reflux is present.

2. Attempting domperidone in the US: The regulatory burden and cardiovascular monitoring requirements make this impractical for first-line use. It's reserved for refractory gastroparesis after metoclopramide failure 1, 2.

3. Ignoring QT prolongation risk with ondansetron: Check baseline ECG in patients with electrolyte abnormalities, heart failure, or concomitant QT-prolonging drugs 7.

4. Masking surgical emergencies: Ondansetron can mask progressive ileus or gastric distension. Monitor for decreased bowel activity, especially post-operatively 7.

5. Serotonin syndrome: Avoid combining ondansetron with SSRIs, SNRIs, or other serotonergic drugs without monitoring for mental status changes, autonomic instability, and neuromuscular symptoms 7.